Tandem Diabetes Care, Inc.’s (TNDM) fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for growth. However, concerns loom over fierce competition and the adverse impact of macroeconomic challenges.In the past year, this Zacks Rank #3 (Hold) company’s shares have declined 38.5% compared with 8.2% decline of the industry and a 10.6% rise of the S&P 500 composite.The renowned medical device company h ...